PhaseBio Signs a Supply Agreement with BioVectra to Support the Development and Commercialization of Bentracimab

Published: Mar 12, 2021 | Tags: PhaseBio, Signs, Supply, Agreement, BioVectra, Support,  Development, Commercialization, Bentracimab

Takeda Reports NDA Submission of Lanadelumab to the MHLW as a Preventive Treatment for Hereditary Angioedema Attack in Japan

Published: Mar 12, 2021 | Tags: Takeda, Reports, NDA, Submission, Lanadelumab, MHLW, Preventive, Treatment, Hereditary Angioedema Attack, Japan

Sanofi and Translate Bio Initiate P-I/II Study of MRT5500 Against COVID-19

Published: Mar 12, 2021 | Tags: Sanofi and Translate Bio, Initiate, P-I/II, Study, MRT5500, Against, COVID-19

Abbott Launches Pandemic Defense Coalition to Detect Future Threats

Published: Mar 12, 2021 | Tags: Abbott, Launches, Pandemic Defense Coalition, Detect, Future, Threats

Astellas Reports NDA Submission of Enfortumab Vedotin to the MHLW for Locally Advanced or Metastatic Urothelial Cancer in Japan

Published: Mar 12, 2021 | Tags: Astellas, Reports, NDA, Submission, Enfortumab Vedotin, MHLW, Locally, Advanced, Metastatic, Urothelial Cancer, Japan

Vir and GSK Report Results of VIR-7831 in P-III COMET-ICE Trial for COVID-19

Published: Mar 12, 2021 | Tags: Vir and GSK, Report, Results, VIR-7831, P-III COMET-ICE, Trial, COVID-19

Vertex's VX-880 Receives the US FDA's Fast Track Designation for T1D

Published: Mar 11, 2021 | Tags: Vertex, VX-880, Receives, US, FDA, Fast Track Designation, T1D

Lannett Receives the US FDA's Feedback for Development of Biosimilar Insulin Glargine

Published: Mar 11, 2021 | Tags: Lannett, Receives, US, FDA, Feedback, Development, Biosimilar Insulin Glargine

Roche's Actemra/RoActemra (tocilizumab) + Veklury Fail to Meet its Primary Endpoints in P-III REMDACTA Study for Patients with Severe COVID-19 Pneumonia

Published: Mar 11, 2021 | Tags: Roche, Actemra/RoActemra (tocilizumab), Veklury, Fail, Meet, Primary Endpoints, P-III REMDACTA, Study, Patients, Severe, COVID-19, Pneumonia

Empatica's Aura System Receives European CE Mark for Detecting Early Symptoms of COVID-19 Using Wearables

Published: Mar 11, 2021 | Tags: Empatica, Aura System, Receives, European, CE Mark, Detecting, Early Symptoms, COVID-19, Wearables

Grifols Acquires Remaining 56% of GigaGen for ~$80M

Published: Mar 11, 2021 | Tags: Grifols, Acquires, Remaining, 56%, GigaGen, ~$80M

Elli Lilly Reports Results of Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) in P-III BLAZE-1 Study for the Prevention of COVID-19

Published: Mar 11, 2021 | Tags: Elli Lilly, Reports, Results, Bamlanivimab, Etesevimab, P-III BLAZE-1, Study, Prevention, COVID-19

Gilead Present Results of Lenacapavir in P-II/III CAPELLA Trial for the Treatment of HIV at CROI

Published: Mar 10, 2021 | Tags: Gilead, Present, Results, Lenacapavir, P-II/III CAPELLA, Trial, Treatment, HIV, CROI

SMA Foundation Collaborates with PTC to Discover and Develop Regenerative Medicine

Published: Mar 10, 2021 | Tags: SMA Foundation, Collaborates, PTC, Discover, Develop, Regenerative Medicine

Sorrento Collaborates with Mount Sinai to Develop Ab Combination for Neutralizing SARS-CoV-2 and other Emerging Variants of COVID-19

Published: Mar 10, 2021 | Tags: Sorrento, Collaborates, Mount Sinai, Develop, Ab, Combination,  Neutralizing, SARS-CoV-2, Emerging Variants, COVID-19

ViiV Healthcare Presents Results of GSK3640254 (GSK-254) in P-IIa study for the Treatment of HIV at CROI

Published: Mar 10, 2021 | Tags: ViiV Healthcare, Presents, Results, GSK3640254 (GSK’254), P-IIa study, Treatment, HIV, CROI

Novartis' Canakinumab Fails to Meet its Primary Endpoint in P-III CANOPY-2 Study

Published: Mar 10, 2021 | Tags: Novartis, Canakinumab, Fails, Meet, Primary Endpoint, P-III CANOPY-2, Study

Takeda to Acquire Maverick for ~$525M

Published: Mar 10, 2021 | Tags: Takeda, Acquire, Maverick, ~$525M

Exelixis Signs an Exclusive License Agreement with WuXi Biologics to Expand its Growing Oncology Biologics Pipeline

Published: Mar 9, 2021 | Tags: Exelixis, Signs, Exclusive, License, Agreement, WuXi Biologics, Expand, Growing, Oncology, Biologics, Pipeline

Roche's Ventana ALK (D5F3) CDx Assay Receives the US FDA's Approval for the Treatment of ALK-Positive NSCLC

Published: Mar 9, 2021 | Tags: Roche, Ventana ALK (D5F3), CDx Assay, Receives, US, FDA, Approval, Treatment, ALK-Positive NSCLC

Abbott Launches NeuroSphere Virtual Clinic for Remote Neurostim Programming in the US

Published: Mar 9, 2021 | Tags: Abbott, Launches, NeuroSphere Virtual Clinic, Remote, Neurostim Programming, US

TrinamiX Signs a Joint Development Agreement with VIAVI Solutions to Bring Near-Infrared Spectroscopy into Smartphones

Published: Mar 9, 2021 | Tags: TrinamiX, Signs, Joint Development Agreement, VIAVI Solutions,  Bring, Near-Infrared Spectroscopy, Smartphones

Lilly Collaborates with Biolojic to Discover and Develop Antibody Therapies for Diabetes

Published: Mar 9, 2021 | Tags: Lilly, Collaborates, Biolojic, Discover, Develop, Antibody, Therapies, Diabetes

Alteogen Reports Completion of P-I Study of ALT-L9 (biosimilar, aflibercept) in Korea

Published: Mar 9, 2021 | Tags: Alteogen, Reports, Completion, P-I Study, ALT-L9 (biosimilar, aflibercept), Korea

Atea Presents Results of AT-527 in P-I Study for COVID 19 at CROI

Published: Mar 8, 2021 | Tags: Atea, Presents, Results, AT-527, P-I Study, COVID 19

Kite's Yescarta Receives the US FDA's Approval for R/R Follicular Lymphoma

Published: Mar 8, 2021 | Tags: Kite, Yescarta, Receives, US, FDA, Approval, R/R Follicular Lymphoma

Gilead Presents Four-Year Data of Biktarvy for HIV-1 in Treatment-Naïve Adults at CROI 2021

Published: Mar 8, 2021 | Tags: Gilead, Presents, Four-Year Data, Biktarvy, HIV-1, Treatment, Naïve Adults

Roche to Withdraw Tecentriq Indication in Metastatic Bladder Cancer in the US

Published: Mar 8, 2021 | Tags: Roche, Withdraw, Tecentriq, Indication, Metastatic, Bladder Cancer US

Lee's Pharma to Initiate P-III Trial of Socazolimab as 1L Treatment of Extensive-stage Small-Cell Lung Cancer

Published: Mar 8, 2021 | Tags: Lee's Pharma, Initiate, P-III Trial, Socazolimab, 1L, Treatment,  Extensive-stage Small-Cell Lung Cancer

ViiV Healthcare Present Results of Long- Acting Cabotegravir and Rilpivirine in P-IIIb ATLAS-2M Study for HIV at CROI 2021

Published: Mar 8, 2021 | Tags: ViiV Healthcare, Present, Results, Long- Acting, Cabotegravir, Rilpivirine, P-IIIb ATLAS-2M, Study, HIV

Related Post: PharmaShots Weekly Snapshots (Mar 01 - 05, 2021)